Analysts’ Weekly Ratings Updates for Intuitive Surgical (ISRG)

Intuitive Surgical (NASDAQ: ISRG) recently received a number of ratings updates from brokerages and research firms:

• 2/7/2026 – Intuitive Surgical was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 2/4/2026 – Intuitive Surgical had its price target lowered by analysts at Argus from $630.00 to $560.00. They now have a “buy” rating on the stock.
• 1/27/2026 – Intuitive Surgical was upgraded by analysts at TD Cowen to a “strong-buy” rating.
• 1/26/2026 – Intuitive Surgical is now covered by analysts at TD Cowen. They set a “buy” rating and a $660.00 price target on the stock.
• 1/26/2026 – Intuitive Surgical was given a new $712.00 price target on by analysts at Barclays PLC. They now have an “overweight” rating on the stock.
• 1/26/2026 – Intuitive Surgical had its price target raised by analysts at HSBC Holdings plc from $644.00 to $653.00. They now have a “buy” rating on the stock.
• 1/23/2026 – Intuitive Surgical had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $620.00 price target on the stock, up previously from $610.00.
• 1/23/2026 – Intuitive Surgical had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $590.00 price target on the stock, down previously from $635.00.
• 1/23/2026 – Intuitive Surgical had its price target raised by analysts at Raymond James Financial, Inc. from $603.00 to $615.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Intuitive Surgical had its price target lowered by analysts at Robert W. Baird from $655.00 to $645.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Intuitive Surgical had its price target lowered by analysts at Evercore Inc from $580.00 to $550.00. They now have an “in-line” rating on the stock.
• 1/23/2026 – Intuitive Surgical had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $616.00 price target on the stock.
• 1/23/2026 – Intuitive Surgical had its price target raised by analysts at Sanford C. Bernstein from $740.00 to $750.00. They now have an “outperform” rating on the stock.
• 1/21/2026 – Intuitive Surgical was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 1/17/2026 – Intuitive Surgical was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/15/2026 – Intuitive Surgical had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 1/9/2026 – Intuitive Surgical had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $740.00 price target on the stock, up previously from $700.00.
• 1/9/2026 – Intuitive Surgical had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $714.00 price target on the stock.
• 1/7/2026 – Intuitive Surgical had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $616.00 price target on the stock, up previously from $589.00.
• 1/7/2026 – Intuitive Surgical had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $686.00 price target on the stock, up previously from $635.00.
• 1/5/2026 – Intuitive Surgical was given a new $580.00 price target on by analysts at Evercore Inc.
• 12/29/2025 – Intuitive Surgical had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Intuitive Surgical had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – Intuitive Surgical had its price target raised by analysts at Truist Financial Corporation from $620.00 to $650.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Intuitive Surgical had its price target raised by analysts at Royal Bank Of Canada from $625.00 to $650.00. They now have an “outperform” rating on the stock.
• 12/15/2025 – Intuitive Surgical had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In other Intuitive Surgical news, Director Gary S. Guthart sold 24,500 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total value of $12,987,450.00. Following the transaction, the director directly owned 3,694 shares in the company, valued at $1,958,189.40. The trade was a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $547.36, for a total value of $2,463,120.00. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company’s stock, valued at $496,455.52. This represents a 83.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 56,189 shares of company stock valued at $30,785,441. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.